Augmedix, Inc.

Equities

AUGX

US05105P1075

Business Support Services

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
2.99 USD -0.66% Intraday chart for Augmedix, Inc. -21.52% -48.89%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Augmedix Insider Sold Shares Worth $369,285, According to a Recent SEC Filing MT
North American Morning Briefing : Traders Await -2- DJ
Augmedix, Inc. Integrates with Andor Health to Revolutionize Ambient Clinical Documentation for Ambulatory Virtual Care CI
Augmedix Insider Sold Shares Worth $454,454, According to a Recent SEC Filing MT
Augmedix Insider Sold Shares Worth $380,108, According to a Recent SEC Filing MT
Augmedix and SADA Forge Partnership to Scale Ambient Documentation and Structured Data Products to Health Systems Nationwide CI
Top Midday Gainers MT
Evercore ISI Adjusts Price Target on Augmedix to $4.50 From $6.50, Maintains In-Line Rating MT
Augmedix Shares Surge 15% Premarket Tuesday as Revenue Growth Beats Expectations, Gross Margins Expand in Q4 MT
Transcript : Augmedix, Inc., Q4 2023 Earnings Call, Mar 18, 2024
Earnings Flash (AUGX) AUGMEDIX Reports Q4 Revenue $12.7M, vs. Street Est of $12.4M MT
Augmedix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Augmedix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Augmedix Provides Revenue Guidance for the Year 2024 CI
Augmedix Announces New Positive Data and Enhancements to Its Ambient AI Product, Augmedix Go CI
Certain Restricted Stock Units of Augmedix, Inc. are subject to a Lock-Up Agreement Ending on 14-FEB-2024. CI
Certain Stock Options of Augmedix, Inc. are subject to a Lock-Up Agreement Ending on 14-FEB-2024. CI
Certain Common Stock of Augmedix, Inc. are subject to a Lock-Up Agreement Ending on 14-FEB-2024. CI
Augmedix Names Tomer Levy as New Senior Vice President of Engineering CI
Augmedix, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Evercore ISI Initiates Augmedix With In Line Rating, Price Target is $6 MT
Waning Optimism on Rate Hike Pause, Cisco Fall Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday MT
Top Premarket Decliners MT
Augmedix Prices $25 Million Share Offering MT
B. Riley Lifts Augmedix's PT to $7.50 From $6.50, Raises 2023 Outlook, Notes Increased Confidence in Business Trajectory; Maintains Buy Rating MT
Chart Augmedix, Inc.
More charts
Augmedix, Inc. helps clinicians and patients form a human connection at the point of care. The Company uses its proprietary Notebuilder Platform to automate the note creation process, aided by its trained MDSs. It also provides data services associated with these products, which include aggregated structured data and metadata associated with medical notes. Its products include Augmedix Live, Augmedix Notes, Augmedix Prep and Augmedix Go. Augmedix Live provides synchronous medical note documentation and point of care support. Augmedix Notes provides asynchronous medical documentation based upon previously recorded visit. Prep provides chart preparation delivered prior to the patient visit. Prep transfers patient demographics, past medical history, medication changes and other key data points from the patient’s health to the current visit note. Clinicians access its products and service through mobile devices, managed by it or their health enterprise.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.99 USD
Average target price
6.1 USD
Spread / Average Target
+104.01%
Consensus
  1. Stock Market
  2. Equities
  3. AUGX Stock
  4. News Augmedix, Inc.
  5. Earnings Flash (AUGX) AUGMEDIX Posts Q2 Revenue $7.3M